Administration of S-nitrosoglutathione after traumatic brain injury protects the neurovascular unit and reduces secondary injury in a rat model of controlled cortical impact by Khan, Mushfiquddin et al.
BioMed  Central
Open Access
Page 1 of 12
(page number not for citation purposes)
Journal of Neuroinflammation
Research
Administration of S-nitrosoglutathione after traumatic 
brain injury protects the neurovascular unit and reduces secondary 
injury in a rat model of controlled cortical impact
Mushfiquddin Khan1, Yeong-Bin Im1, Anandakumar Shunmugavel1, 
Anne G Gilg1, Ramanpreet K Dhindsa1, Avtar K Singh2,3 and Inderjit Singh*1
Address: 1Department of Pediatrics, Medical University of South Carolina, Charleston, SC 29425, USA, 2Department of Pathology and Laboratory 
Medicine, Medical University of South Carolina, Charleston, SC 29425, USA and 3Ralph H. Johnson V. A. Medical Center, Charleston, SC 29401, 
USA
Email: Mushfiquddin Khan - khanm@musc.edu; Yeong-Bin Im - imyb@musc.edu; Anandakumar Shunmugavel - anandak@musc.edu; 
Anne G Gilg - gilg@musc.edu; Ramanpreet K Dhindsa - mushfiquddinkhan@gmail.com; Avtar K Singh - singha@musc.edu; 
Inderjit Singh* - singhi@musc.edu
* Corresponding author    
Abstract
Background: Traumatic brain injury (TBI) is a major cause of preventable death and serious morbidity in young
adults. This complex pathological condition is characterized by significant blood brain barrier (BBB) leakage that
stems from cerebral ischemia, inflammation, and redox imbalances in the traumatic penumbra of the injured brain.
Once trauma has occurred, combating these exacerbations is the keystone of an effective TBI therapy. Following
other brain injuries, nitric oxide modulators such as S-nitrosoglutathione (GSNO) maintain not only redox
balance but also inhibit the mechanisms of secondary injury. Therefore, we tested whether GSNO shows efficacy
in a rat model of experimental TBI.
Methods: TBI was induced by controlled cortical impact (CCI) in adult male rats. GSNO (50 μg/kg body weight)
was administered at two hours after CCI. GSNO-treated injured animals (CCI+GSNO group) were compared
with vehicle-treated injured animals (CCI+VEH group) in terms of tissue morphology, BBB leakage, edema,
inflammation, cell death, and neurological deficit.
Results: Treatment of the TBI animals with GSNO reduced BBB disruption as evidenced by decreased Evan's
blue extravasation across brain, infiltration/activation of macrophages (ED1 positive cells), and reduced
expression of ICAM-1 and MMP-9. The GSNO treatment also restored CCI-mediated reduced expression of BBB
integrity proteins ZO-1 and occludin. GSNO-mediated improvements in tissue histology shown by reduction of
lesion size and decreased loss of both myelin (measured by LFB staining) and neurons (assayed by TUNEL) further
support the efficacy of GSNO therapy. GSNO-mediated reduced expression of iNOS in macrophages as well as
decreased neuronal cell death may be responsible for the histological improvement and reduced exacerbations.
In addition to these biochemical and histological improvements, GSNO-treated injured animals recovered
neurobehavioral functions as evaluated by the rotarod task and neurological score measurements.
Conclusion: GSNO is a promising candidate to be evaluated in humans after brain trauma because it not only
protects the traumatic penumbra from secondary injury and improves overall tissue structure but also maintains
the integrity of BBB and reduces neurologic deficits following CCI in a rat model of experimental TBI.
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Background
Immediately following traumatic brain injury (TBI), the
direct trauma and lack of cerebral blood flow (CBF) to
injured tissue cause necrotic neuronal cell death. How-
ever, even greater apoptotic neuronal loss occurs hours
and days later as a result of secondary injury from cerebral
ischemia/hypoxia, blood brain barrier (BBB) leakage, and
inflammatory/oxidative stress [1]. In this respect, TBI has
similar pathophysiology to ischemic stroke. Both have
hypoxia, disrupted BBB, edema, inflammation, neurode-
generation, and neurological deficits [2,3]. Furthermore,
the time-dependant progression of the disease presents a
window of opportunity to reduce secondary injury-medi-
ated damage in both stroke and TBI. Regional ischemia
early after TBI and a relationship between the volume of
ischemic tissue and neurological outcomes have been
reported [2].
However, major clinical trials with drugs that target only
neuroprotection following TBI have proven to be of little
efficacy [4]. TBI is a complex disease involving multiple
tissues such as vasculature, vascular immune cells, and
various cell types within the central nervous system
(CNS). The failure of therapies targeted only to neuronal
protection is attributable, in part, to the lack of concomi-
tant protection of cerebral blood vessels from the second-
ary injury of inflammation and reactive oxygen species/
reactive nitrogen species (ROS/RNS) stress. Recently, we
have documented that S-nitrosoglutathione (GSNO), a
nitric oxide (NO) modulator and endogenous nitrosylat-
ing agent, not only protects endothelial function from
oxidative and inflammatory injuries [5] but also lessens
ischemia reperfusion (IR) injury in a rat model of experi-
mental stroke [6,7]. We hypothesize a similar efficacy of
GSNO in ameliorating the secondary injury components
of TBI. Therefore, we tested its therapeutic potential in a
rat model of controlled cortical impact (CCI).
GSNO is a physiological metabolite of glutathione (GSH)
and NO [8,9]. It is involved in several pharmacological
activities [10] and cellular signaling [11-15]. GSNO is
present in micromolar concentrations in the rat brain
[16]. It is several-fold more potent than GSH against oxi-
dative stress caused by ONOO- [17]. Unlike other classes
of NO donor, GSNO is a stable compound and does not
decompose spontaneously; it requires additional agents
or enzymes, including GSNO reductase or the thioredoxin
system [18,19], for its metabolism. It reduces the fre-
quency of embolic signals [20-22] and can reverse acute
vasoconstriction, preventing ischemic brain injury after
subarachnoid hemorrhage [23]. Administration of GSNO
has been shown to suppress inducible nitric oxide syn-
thase (iNOS) induction and enhance endothelial nitric
oxide synthase (eNOS) expression in pedicle vessels,
resulting in blood perfusion and a higher flap survival
after I/R [24,25]. In animals, GSNO treatment blocks
inflammation and secondary injury in the brain following
IR [6,7]. The deleterious role of inflammation in TBI is
also reported to be mediated via induction of cytokines,
chemokines and iNOS [26]. Expression of iNOS has been
shown at 3 to 7 days after TBI in adult rats, predominantly
in macrophages, and its pharmacological inhibition by
aminoguanidine reduces TBI [27], supporting the concept
that down regulation of iNOS in TBI is beneficial. The
antiinflammatory activity of GSNO in down regulating
iNOS is mediated by the inhibition of NF-κB activation in
rat primary astrocytes and microglial cell lines [7].
Injuries that compromise the integrity of the BBB lead to
the activation of endothelial cells and the recruitment of
inflammatory cells in the CNS. Increased expression of
ICAM-1 and MMP-9 has been reported in TBI, and the
ICAM-1 antibody is reported to improve recovery follow-
ing TBI [28]. MMP-9 can degrade crucial components of
BBB and exacerbate edema. Moreover, its expression is
associated with inflammation [29]. Following TBI, BBB
disruption is a common clinical condition which leads to
an increase in intracranial pressure caused by severe brain
edema. Brain edema is formed due to cellular injury and
circulatory collapse [30]. The microvascular permeability
increases due, in part, to secondary oxidative stress
[31,32], which is related to endothelial cell activation and
endothelial dysfunction. Suppression of neuroinflamma-
tion and edema improves functional and neurologic out-
comes [26].
Neurobehavioral deficits, especially in motor and cogni-
tive functions, are often the cause of significant disability
and morbidity after TBI. Motor impairments after moder-
ate-to-severe TBI play a significant role in the initial recov-
ery phase [33]. Determining the extent of clinically
relevant neuropathology (defined as neuropathology
associated with persistent neurobehavioral deficits) asso-
ciated with TBI, particularly in the milder spectrum, is
problematic. Nevertheless, evaluation of improvement in
neurological function using a clinically relevant TBI
model such as controlled cortical impact (CCI) estab-
lishes the efficacy and the clinical relevance of an experi-
mental therapy [34].
The results in this study document that treatment of the
injured rats at two hours after CCI with GSNO reduced
BBB leakage and improved neurobehavioral functions.
The treatment also blocked infiltration of macrophages
and reduced the expression of ICAM-1, MMP-9, and
iNOS. GSNO also inhibited the TBI-mediated decrease in
the expression of ZO-1 and occludin. Improvement in tis-
sue histology and decreased loss of both myelin and neu-
rons in the GSNO-treated injured group further support
the efficacy of the GSNO therapy.Journal of Neuroinflammation 2009, 6:32 http://www.jneuroinflammation.com/content/6/1/32
Page 3 of 12
(page number not for citation purposes)
Methods
Reagents
GSNO was purchased from World Precision Instruments
(Sarasota, FL). All other chemicals and reagents used were
purchased from Sigma (St. Louis, MO), unless stated oth-
erwise.
Animals
Male Sprague-Dawley rats weighing 240-260 g (Harlan
Laboratories, Wilmington, MA) were used in this study.
All animal procedures were approved by the Medical Uni-
versity of South Carolina Animal Review Committee and
received humane care in compliance with the Medical
University of South Carolina's experimental guidelines
and the National Research Council's criteria for humane
care (Guide for the Care and Use of Laboratory Animals).
Experimental design and administration of GSNO
The rats were randomly allocated into the three groups: i)
Sham (sham-operated control, n = 29), ii) CCI+VEH
(vehicle-treated CCI, n = 29), iii) CCI+GSNO (GSNO-
treated CCI, n = 29). Because GSNO-treated sham animals
(n = 5) had no altered physiologic parameters including
blood pressure (BP) and heart rate (HR) (data not
shown), we did not include the Sham+GSNO group for
further study. In the CCI+GSNO group, the rats were given
GSNO (50 μg/kg body weight), dissolved in sterile PBS
(~300 μl) by mouth using gavage needle at 2 hours after
CCI. The rats in the CCI+VEH and the Sham groups were
administered the same volume of PBS. The same dose of
GSNO was repeated every 24 hours by mouth until the
end point as described under each experiment. The dose
used in this study was determined by a dose response
curve ranging from 10 μg to 100 μg/kg body weight. The
dose 50 μg/kg was found most effective in reducing con-
tusion volume measured at 7 days after CCI. The selected
dose did not alter physiologic parameters, including BP,
HR, and temperature, measured at 1 hour following
GSNO treatment. Similar observations with low dose
GSNO treatments were made in the experimental stroke
study [6,7]. Therefore, we did not include data from phys-
iologic measurements in this study.
Controlled cortical impact (CCI) model of TBI
Surgical anesthesia was induced by ketamine (90 mg/kg
body weight) and xylazine (10 mg/kg body weight)
administered intraperitoneally (ip). Analgesic buprenor-
phine was administered pre-emptively to alleviate the
pain following surgery. Following endotracheal intuba-
tion, the animals were secured in a stereotaxic frame and
ventilated mechanically. A dab of sterile ophthalmic oint-
ment was placed on each eye to compensate for the
decrease in lacrimation during anesthesia. Utilizing asep-
tic techniques, a midline scalp incision was made, and the
skin and fascia were reflected to expose the skull. A crani-
otomy was made in the right hemisphere encompassing
bregma and lambda and between the sagittal suture and
the coronal ridge with a handheld Michele trephine. The
resulting bone flap was removed, and the craniotomy
enlarged further with cranial rongeurs. CCI injury was
produced as previously described in the extensive litera-
ture [34-39]. A cortical contusion was produced on the
exposed cortex using a controlled impactor device TBI-
0310 TBI Model system (Precision Systems and Instru-
mentation, LLC, Fairfax Station, VA). Briefly, the impact-
ing shaft was extended, and the impact tip was centered
and lowered over the craniotomy site until it touched the
dura mater. Then, the rod was retracted and the impact tip
was advanced farther to produce a brain injury of moder-
ate severity for rats (tip diameter, 4 mm; cortical contu-
sion depth, 3 mm; impact velocity, 1.5 m/sec) [37]. The
impact tip was wiped clean with sterile alcohol after each
impact and cleaned/disinfected further with cidex after
surgery. Core temperature was maintained at 37 ± 0.5°C
with a heating pad during surgery and recorded with a rec-
tal probe. Immediately after injury, the skin incision was
closed with nylon sutures, and 2% lidocaine jelly was
applied to the lesion site to minimize any possible dis-
comfort.
Histology
The paraffin embedded brain was sectioned at a thickness
of 4 μM using a Leica 2135 microtome (Deerfield, IL,
USA). Brain sections following CCI were evaluated for tis-
sue histology by morphometric analysis using Hematoxy-
lin and Eosin (H&E) and Luxol Fast Blue (LFB)-PAS
staining as described earlier [40].
Lesion size measurement
Seven days after CCI, brains were removed, sectioned and
stained with H&E. The images of the stained specimens
were captured by a digital photo camera and analyzed by
Image Pro for morphometric measurement. The total
lesion volume was determined by integrating the volumes
at each coronal section interval as reported [41,42]. A
blind investigator performed the lesion volume analyses.
Evaluation of BBB disruption by Evan's blue (EB) 
extravasation
BBB leakage was assessed by the method of Weismann
and Stewart [43] with slight modification. The rats
received 100 μl of a 5% solution of EB in saline adminis-
tered intravenously at 4 hours after CCI. At 48 hours, car-
diac perfusion was performed under deep anesthesia with
200 ml of saline to clear the cerebral circulation of EB. The
brain was removed, sliced, and photographed. The two
hemispheres were isolated and mechanically homoge-
nized in 750 μl of N, N-dimethylformamide (DMF). The
suspension obtained was kept at room temperature in the
dark for 72 hr. It was centrifuged at 10,000 × g for 25 min-Journal of Neuroinflammation 2009, 6:32 http://www.jneuroinflammation.com/content/6/1/32
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utes, and the supernatant was spectrofluorimetrically ana-
lyzed (λex 620 nm, λem 680 nm).
Measurement of Edema (brain water content)
At 24 h following CCI, animals were euthanized to deter-
mine brain water content (edema). The cortices, excluding
the cerebellum, were quickly removed, and the contralat-
eral and ipsilateral hemispheres separately weighed. Each
hemisphere was dried at 60°C for 72 hours, and the dry
weight was determined. Water content was calculated in
ipsilateral hemisphere as: water content (%) = (wet weight
- dry weight)/wet weight × 100.
Immunohistochemistry
Paraffin-embedded sections from the formalin-fixed brain
tissues were stained for ED1, ICAM-1, and MMP-9. In
brief, the brain tissue sections were deparaffinized,
sequentially rehydrated in graded alcohol, and then
immersed in PBS (pH 7.4). Slides were then microwaved
for 2 mins in antigen unmasking solution (Vector Labs),
cooled, and washed 3 times for 2 mins in PBS. Sections
were incubated overnight with antibodies of ED1 (Accu-
rate, Westbury, NY, USA), ICAM-1 (BD Pharmingen, San
Jose, CA, USA), MMP-9, and iNOS (Santa Cruz Biotech-
nology Inc, Santa Cruz, CA, USA). They were then rinsed
3 times for 5 mins in PBS containing 0.1% Tween-20. Sec-
ondary anti- anti-mouse IgG conjugated with Alexa Fluor
488 was incubated on slides for 30 mins. Slides were
examined for immunofluorescence in the traumatic
penumbra area using an Olympus microscope equipped
for epifluorescence and DP Controller software. Figures
were compiled in Adobe Photoshop 7.0.
For double labeling, section was incubated first with anti-
body of iNOS followed by specific cell marker antibodies
(GFAP, ED1, CD34, or NSE). For immunofluorescent
double-labeling, immune complexes were visualized with
Texas Red conjugated anti-rabbit IgG (1:100, Vector Labs)
and FITC conjugated anti-mouse IgG (1:100, Vector
Labs). Rabbit polyclonal IgG was used as a control pri-
mary antibody. Section was also incubated with FITC or
Texas Red conjugated IgG without the primary antibody
as a negative control. Slides were examined for immun-
ofluorescence using an Olympus microscope equipped
for epifluorescence filter and Adobe Photoshop software
[7].
Cell counting was performed in three equi-distant sec-
tions (10 sections apart) from each brain and expressed as
an average number of immunopositive cells per section.
The positive cells were counted on each section at 400 ×
magnification (one visual field = 0.69 mm2) using an
Olympus microscope equipped for epifluorescence and
DP Controller software. Images were captured and proc-
essed using Adobe Photoshop 7.0.
Fluorescent TUNEL assay for detection of apoptosis
Terminal deoxynucleotidyl transferase-mediated bioti-
nylated UTPnick end labeling (TUNEL) assay was per-
formed in the traumatic penumbra region by using an
Apoptagfluorescein in situ apoptosis detection kit (Sero-
logical Corporation, Norcross, GA, USA) according to the
manufacturer's protocol. For double labeling, brain sec-
tions from three animals in each experimental group were
probed with mouse NSE (Chemicon-Millipore Billerica,
MA, USA) and visualized by fluorescence microscopy as
described previously [7]. TUNEL/NSE double positive
cells were counted in at least ten microscopic frames of the
sections and in equivalent areas of sections from animals
in GSNO group.
Western blot analysis
Western blot was performed in the traumatic penumbra
area from the ipsilateral injured brain and a similar area
from the control and/or contralateral tissues using anti-
bodies ZO-1, occludin (Invitrogen Corporation, Carlsbad,
CA, USA), and β-actin, as described earlier [7,44]. Protein
concentrations were determined using protein assay dye
from Bio-Rad Laboratories (Hercules, CA, USA).
Neurological functional evaluation
Neurological motor measurement was performed using
the Modified Neurological Severity Score (mNSS) as
described [45]. These tests were performed on all rats 1
day before and after 6 days of CCI. All measurements were
performed by observers blinded to treatment. The test is
sensitive to unilateral cortical injury because it reflects
multiple asymmetries, including postural, sensory, and
forelimb and hind limb use asymmetries. A detailed
description of this functional test has been previously
reported [46]. Briefly, this motor test (total score points
18) is based on 1) raising the rat by tail and recording flex-
ion (3 points), 2) walking on the floor (3 points), 3) sen-
sory test (2 points), 4) beam balance tests (6 points), and
reflexes absence and abnormal movements (4 points).
Point is awarded for the inability to perform the tasks or
for the lack of a tested reflex. Levels of injury in animals
are determined as severe (13-18 points), moderate (7-12
points) and mild (1-6 points).
Sensorimotor deficit behavioral test
Sensorimotor deficit was assessed by investigators blinded
to the study conditions by the adhesive tape-removal test
before CCI and 7, 14, and 21 days after. Two pieces of
adhesive-backed paper dots (113.1 mm2) were used as
bilateral tactile stimuli attached at the distal-radial region
on each forelimb. The latency was recorded (the time to
remove each stimulus from the forelimbs) during three
trials per day for each forepaw as described [47]. Before
injury, rats were trained for 3 days. The test has been vali-
dated in a CCI rat model of TBI [48].Journal of Neuroinflammation 2009, 6:32 http://www.jneuroinflammation.com/content/6/1/32
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Rotarod
Latency on rotarod was measured using the Rotarod sys-
tem (Rotomex 5) from Columbus Instruments, Colum-
bus, OH, by trained personnel blinded to animal groups
as described [49-52]. Animals were pre-trained on an
automated 4-lane rotarod unit and the task was per-
formed up to two weeks after CCI. The animal was placed
on the rod and tested for its latency period. The starting
speed was set to 0, and the speed was increased by 2 rpm
every 5 seconds up to 30 rpm. Total time in seconds that
the animal could stay on the drum was recorded. Each
animal was given 3 trials, and the mean latency of three
trials was calculated for each animal.
Statistical evaluation
Statistical analysis was performed as described [53] using
software Graphpad Prism 3.0. Unless otherwise stated, all
the values were expressed as mean ± SD of n determina-
tions or as mentioned. The results from biochemical and
animal behavior studies were examined by unpaired t-
test. Multiple comparisons were performed using Kruskal-
Wallis test or using ANOVA followed by Bonferroni test as
appropriate. A p value less than 0.05 was considered sig-
nificant.
Results
GSNO is protective in CCI model of TBI and reduces 
expression of ED1 and ICAM-1
We have previously documented GSNO not only as a
potent neuroprotective agent but also as an endothelium
protecting agent in a rat model of experimental stroke.
Therefore, we investigated whether the IR injury-reducing
agent GSNO also reduces neurovascular injury when
administered in a clinically relevant 2 hours post-injury
rat CCI model of TBI. Animals were administered GSNO
(0.05 mg/kg, orally) or PBS (VEH) at 2 h following CCI.
The same dose was repeated every 24 h by mouth until the
animals were sacrificed. Brain sections at day 7 following
CCI were evaluated for tissue histology by morphometric
analysis using Hematoxylin and Eosin (H&E) (Fig 1A)
and (Luxol Fast Blue (LFB)-PAS staining (Fig 1C). Contu-
sion size analysis was performed using H&E sections (Fig
1B).
GSNO treatment significantly improved tissue structure/
morphology and reduced contusion size (62.3 ± 7.9 vs.
20.4 ± 2.8 GSNO; p < 0.001) (Fig 1A-B), supporting the
potential of GSNO therapy in TBI. The treatment with
GSNO also improved LFB staining (Fig 1C), indicating
further that GSNO protected against the loss of myelin
following TBI. Furthermore, GSNO decreased the expres-
sion of ICAM-1 (Fig 1D) (a mediator of endothelial cell
activation leading to BBB disruption) and ED-1 (Fig 1E) (a
marker of activated macrophages and microglia) deter-
mined at 72 h after CCI. Enhanced expression of ICAM-1
together with ED-1 in the traumatic penumbra region of
the injured brain indicates infiltration of immune cells
into the brain due to disruption of BBB.
GSNO protects BBB integrity by reducing its leakage, 
enhancing expression of ZO-1 and occludin, and 
decreasing both edema and the expression of MMP-9
BBB disruption and edema are the hallmarks of TBI, lead-
ing to inflammation, secondary injury, and cell death
[30]. An assessment by the EB extravasation method
showed reduced BBB leakage in the CCI+GSNO group
compared to the CCI+VEH group (Fig 2A). Evaluation of
EB color in each animal by an observer blinded to the
groups found decreased intensity in the CCI+GSNO
group compared to the CCI+VEH group (Table 1), indi-
cating the efficacy of GSNO for BBB protection. The
results were further supported by decreased edema/water
content in the ipsilateral side of the CCI+GSNO group
compared to the CCI+VEH group (Fig 2C). To support
that GSNO blocks BBB leakage, we determined the expres-
sion of proteins (ZO-1 and occludin, Fig 2B) involved in
maintaining the integrity of BBB using Western blot and
the expression of MMP-9 (immunohistochemistry, Fig
2D) following TBI in the traumatic penumbral area from
the ipsilateral hemisphere. The expression of ZO-1 and
occludin was decreased in the CCI+VEH brain (Fig 2B),
whereas the expression of MMP-9 was increased (Fig 2D).
Effect of GSNO treatment on TBI-mediated tissue injury and  on the expression of ICAM-1 and ED1 in ipsilateral rat brain  after CCI Figure 1
Effect of GSNO treatment on TBI-mediated tissue 
injury and on the expression of ICAM-1 and ED1 in 
ipsilateral rat brain after CCI. Animals were treated with 
GSNO (0.05 mg/kg) 2 h following CCI. Seven days after TBI, 
brains were removed, sectioned and stained with H&E (A) 
and LFB (C) and analyzed for lesion size (B) using morpho-
metric measurement. GSNO reduced TBI-mediated tissue 
injury, decreased lesion size (B), and reduced the expression 
of ICAM-1 (D) and ED1 (E) (detected in traumatic penum-
bral area at 72 h following TBI). Photomicrographs are the 
representative of n = 3 in each group. Lesion size data are 
presented as mean ± SD (n = 3). ***p < 0.001 vs. CCI+VEH.Journal of Neuroinflammation 2009, 6:32 http://www.jneuroinflammation.com/content/6/1/32
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The expression of MMP-9 was also found increased
around the vessel in CCI+VEH brain (upper panel Fig
2D). The treatment with GSNO enhanced the expression
of ZO-1 and occludin (Fig 2B), and decreased the expres-
sion of MMP-9 (Fig 2D), indicating its potential for BBB
protection.
GSNO reduces the expression of proinflammatory 
mediator iNOS in macrophage/microglia
iNOS was highly expressed at 72 h after CCI in the trau-
matic penumbral area of CCI+VEH compared to Sham
brain as shown by immunohistochemical staining. Treat-
ment of the injured animals with GSNO decreased TBI-
mediated expression of iNOS (Fig 3A). We also identified
that iNOS expression was present mainly in ED1-postive
cells (Fig 3B), indicating participation of macrophages/
microglia via iNOS in TBI-induced injury.
GSNO aids recovery and improves neurobehavioral 
function
Neurological deficit was evaluated using three different
tests. To assess motor function, we used the rotarod task,
which is reportedly the most sensitive vestibulomotor
measure [33]. GSNO treatment of the injured animals
gradually but significantly improved latency, and hence,
motor functions, following TBI (Fig 4A) as evaluated by
the rotarod task [50,54]. We also observed improvements
in neurological score and sensory testing (Fig 4B-C). Neu-
rological score was determined using the modified neuro-
logical severity score test (mNSS) at the 6th day following
CCI as described recently in TBI [45]. The score was signif-
icantly improved in the CCI+GSNO group compared to
the CCI+VEH group (5.8 ± 01.0 CCI+GSNO vs. 9.2 ± 1.0
CCI+VEH, p < 0.01). Sensory dysfunction was assessed
using the tactile adhesive removal test [47,48], which was
significantly improved in the CCI+GSNO group com-
pared to the CCI+VEH group as shown in Fig 4C.
GSNO reduces neuronal apoptotic cell death
DNA fragmentation (measured by TUNEL assay) in the
traumatic penumbral area of the CCI+VEH brain at 72 h
was increased significantly. GSNO treatment resulted in a
decreased number of TUNEL-positive cells (Fig 5A, C).
Neither Sham nor the contralateral hemishphere (not
shown) of CCI+VEH brain showed TUNEL-positive cells.
The fact that TUNEL-positive cells were mainly neurons
was confirmed by colocalization of the TUNEL staining
with the neuron-specific marker-NSE (Fig 5B, D).
Discussion
GSNO improved neurobehavioral functions and reduced
apoptotic cell death, inflammation and BBB leakage.
Other GSNO-mediated effects were decreased contusion
volume, improved tissue structure, and reduced edema.
GSNO also decreased the expression of MMP-9. In sum,
the neurovascular protection rendered by GSNO in the
Table 1: Effect of CCI and protection by GSNO on BBB 
permeability assessed by macromolecular tracer dye Evan's 
blue.
Group # of animal showing staining/total # of animals
0 + ++ +++
Sham 5/5 0/5 0/5 0/5
CCI+VEH 0/7 1/7 3/7 3/7
CCI+GSNO 0/7 4/7 2/7 1/7
Qualitative assessment of Evan's blue (EB) dye using a standard 
procedure of grading as described by Rapoport et al [77] and as given: 
0 = no staining; + = mild staining; ++ = moderate staining; +++ = 
heavy staining. Experimental details of EB extravasation are described 
in Methods. Animals were treated with GSNO (0.05 mg/kg) at 2 h 
following CCI. CCI+VEH and Sham animals were treated with the 
vehicle (PBS). n = 5 (Sham) and n = 7 (CCI+VEH and CCI+GSNO).
Effect of GSNO on TBI-mediated BBB disruption, edema and  on the expression of ZO-1, occludin and MMP-9 in ipsilateral  rat brain after CCI Figure 2
Effect of GSNO on TBI-mediated BBB disruption, 
edema and on the expression of ZO-1, occludin and 
MMP-9 in ipsilateral rat brain after CCI. Representative 
photographs showing Evan's blue extravasation at 48 h in 2 
out of 6 coronal sections (A). Significant EB leakage was 
observed in CCI+VEH brain, and the leakage was reduced in 
the CCI+GSNO group. EB extravasation was not observed 
in Sham animals (see Table 1). A similar treatment with 
GSNO decreased the brain water content (edema) in ipsilat-
eral brain (C) measured at 24 h after CCI. Treatment with 
GSNO also enhanced TBI-mediated reduced expression of 
ZO-1 and occludin in traumatic penumbral area from ipsilat-
eral hemisphere measures at 24 h following TBI by Western 
blot (B). TBI-mediated increased expression of MMP-9 was 
also decreased following GSNO treatment (detected in trau-
matic penumbral area at 72 h following TBI) (D). Photomi-
crograph of Evan's blue is the representative of n = 5. Edema 
data are presented as mean ± SD (n = 5). Western blot and 
photomicrographs of MMP-9 immunohistochemistry are rep-
resentative of n = 3 in each group. *p < 0.05 vs. CCI+VEH or 
Sham. ips, ipsilateral; conr, contralateral.Journal of Neuroinflammation 2009, 6:32 http://www.jneuroinflammation.com/content/6/1/32
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CCI model of TBI is achieved not only through anti-
inflammatory and antioxidant mechanisms but also via
BBB-protecting activities and mechanisms that aid func-
tional recovery.
Animal models of TBI using the CCI technique are physi-
ologically relevant to TBI in humans. CCI reproduces
many of the features of brain injuries, including motor
deficits, memory loss, and neuron loss [34,39,55,56]. The
severity of injury can be controlled by altering the velocity
and depth of the impact and the size of the impactor tip
[57]. It is recognized that very severe injury involves sev-
eral pathways, thus making it difficult to delineate the crit-
ical ones. We therefore used a moderate TBI model as
described in Methods and reported previously [34,35,39].
Immediately following TBI, the direct trauma and lack of
blood flow cause necrotic neuronal death. However, even
greater apoptotic neuronal loss occurs hours and days
later, caused by secondary injury from cerebral ischemia/
hypoxia as well as inflammatory and oxidative stress. Evi-
dence for the existence of a 'traumatic penumbra' (tissue
that is most at risk of secondary ischemic injury and that
will be most affected by changes in physiology or thera-
peutic interventions) has been shown in human traumatic
head injury [2,3]. In this respect, TBI has similar patho-
physiology to ischemic stroke. Both have hypoxia, dis-
rupted BBB, edema, inflammation, neurodegeneration,
and neurological deficits. Furthermore, the time-depend-
ant progression of the disease presents a window of
opportunity to reduce secondary injury-mediated damage
in both stroke and TBI. Regional ischemia early after TBI
has been shown to correlate with neurological outcome
[2]. The majority of patients who die from TBI demon-
strate cerebral ischemia, which may be an important sec-
ondary event affecting outcome following TBI. CBF is
approximately half normal following TBI in the first 24 h
[58], and alterations in vascular functions are mainly due
to endothelial dysfunction and reduced NO bioavailabil-
ity, which leads to oxidative exacerbations and BBB leak-
age. Decreased levels of NO have been reported in plasma
from stroke patients and in animal brain tissue after
experimental TBI, indicating an abnormality of NO
metabolism after acute injury [59,60]. Decreased NO lev-
els may be responsible for the decrease in CBF and the
consequent BBB leakage as well as cell death. To support
the pathology associated with the decrease in NO level,
NO donors and L-arginine (the substrate of NOSs) are
reported to reduce TBI [61,62]. These observations indi-
cate that targeting the NO modulating system is an attrac-
tive approach for developing TBI therapy.
To date, major clinical trials with neuroprotective drugs
that targeted TBI amelioration have not been efficacious
[4]. The failure of therapies targeted only to neuronal pro-
tection is, in part, attributable to the lack of concomitant
protection of cerebral blood vessels from the secondary
injury of inflammation and accumulating oxidative exac-
erbations. An inhibition of inflammation and reduction
of oxidative exacerbations by a post-stroke injury treat-
ment with the NO-modulating agent GSNO resulted in an
increased CBF as well as neurovascular protection, leading
to improved neurological symptoms in a rat model of
experimental stroke [7]. CBF is dependent in part on
vasodilation, which is mainly regulated by NO. NO bioa-
vailability in the endothelium is reduced following TBI
due to its diffusion-limited reaction with superoxide,
resulting in the formation of peroxynitrite. We have
reported earlier that GSNO increased CBF in stroke ani-
mals [6]; therefore, GSNO possesses the potential to
maintain BBB integrity via its hemodynamic activity. Our
studies found that NO donors belonging to structurally
different classes increase CBF. However, only those NO
donors which possessed a nitrosylating property (e.g.
GSNO and SNAP) were protective [6], indicating that
enhancing CBF only is insufficient to provide neurovascu-
lar protection. Therefore, we opted for the nitrosylating
agent GSNO to investigate whether it has neurovascular
protective effects in experimental TBI similar to that in
experimental stroke.
Effect of GSNO on the expression of iNOS present mainly in  macrophages/microglia Figure 3
Effect of GSNO on the expression of iNOS present 
mainly in macrophages/microglia. Red fluorescence 
indicates induced higher expression of iNOS in the traumatic 
penumbral area of CCI+VEH brain than in the treated 
(CCI+GSNO) brain determined by immunohistochemistry at 
72 h following CCI. Sham animal did not show any significant 
staining of iNOS (A). Colocalization of the expression of 
iNOS with ED1 as yellowish fluorescence (B) indicates that 
iNOS was mainly expressed in macrophages/microglia.Journal of Neuroinflammation 2009, 6:32 http://www.jneuroinflammation.com/content/6/1/32
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GSNO functions in vivo mainly via nitrosylation of pro-
tein thiols in health and disease [63,64]. It is an endog-
enous nitrosylating agent [8], and its homeostasis is
maintained in blood and tissues [65]. Abnormalities in S-
nitrosylation cause diseases, as is evident from S-nitro-
sothiol depletion in asthma [66] and amyotrophic lateral
sclerosis [67]. Depletion of plasma-nitrosylated species
has also been observed in patients with endothelial dys-
function [68]. However, under certain circumstances,
GSNO may release NO and function as an NO donor.
Unlike conventional NO donors which release NO
quickly and with high density, nitrosylating agents such as
GSNO and SNAP release NO slowly and invoke neurovas-
cular protective effects following IR [6,7]. We also
reported previously that treatment with GSNO reduces
not only neuronal cell death and glial cell inflammation
but also reduces endothelial cell activation evaluated as
the expression of ICAM-1 and E-selectin [6,7], indicating
the potential of GSNO therapy for the protection of BBB
following acute brain injury. Later, we found that inhibi-
tion of endothelial cell activation was dependent on
GSNO-mediated nitrosylation of the p65 subunit of NF-
κB [5]. Because activation of endothelial cells via
increased expression of ICAM-1 is directly involved in
BBB disruption and inactivation of ICAM-1 provides pro-
tection in BBB [69], we investigated the GSNO interven-
tion's effect on BBB protection in this study. GSNO
decreased EB extravasation (a measure of BBB leakage)
following TBI (Fig 2A and Table 1), supporting our in vitro
results [5] that GSNO protects BBB integrity. We also
found decreased expression of ICAM-1 (Fig 1D) and the
consequent inhibition of infiltration/activation of macro-
phages/microglia (ED1) (Fig 1E). Along with the expres-
sion of CAMs, the degradation of basal lamina and
activation of MMP-9 was also observed following TBI
[29]. The observed decreased expression of MMP-9 and
protection against degradation of the basal lamina in the
GSNO group (Fig 2D) support the efficacy of GSNO for
BBB protection. Expression of both ICAM-1 and MMP-9
are regulated by NF-κB; therefore, GSNO may reduce the
Effect of GSNO on TBI-mediated deficits in neurobehavioral function Figure 4
Effect of GSNO on TBI-mediated deficits in neurobehavioral function. A treatment at 2 h post-injury following CCI 
with GSNO improved motor function evaluated by rotarod task (A), decreased modified neurological severity score (mNSS) 
(B) evaluated on 6th day after CCI and reduced time to remove the stimuli from limbs (tactile strength test) (C). Data are pre-
sented as mean ± SD (n = 7). ***p < 0.001, **p < 0.01, *p < 0.05 vs. CCI+VEH.Journal of Neuroinflammation 2009, 6:32 http://www.jneuroinflammation.com/content/6/1/32
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expression of both MMP-9 and ICAM-1 via inhibition of
NF-κB through nitrosylation of the P65 subunit of NF-κB
as reported earlier [5]. Overall, GSNO treatment resulted
in improved tissue morphology (H&E staining, Fig 1A),
reduced contusion volume (Fig 1B), and reduced loss of
myelin (Fig 1C), suggesting that these morphometric
improvements are achieved due to GSNO-mediated BBB
protection. Consistent with our finding of GSNO-medi-
ated BBB protection, the role of GSNO in down regulation
of inflammation and protection of the intestinal barrier
has also recently been reported [70].
The BBB is a neurovascular system mainly composed of
endothelial and astroglial cells with a basal lamina. It is
highly discriminatory and has selective permeability
inside the brain. Tight junction-associated proteins such
as ZO-1 and occludin play critical roles in maintaining
BBB functions [71]. We therefore investigated the status of
these tight junction proteins and observed that TBI
reduced the levels of both ZO-1 and occludin examined at
24 h following CCI (Fig 2B). Protection by GSNO against
the TBI-mediated loss of ZO-1 and occludin suggests that
GSNO protects endothelial tight junctions and therefore
keeps the BBB intact. Interestingly, ZO-1 has been
reported to contain a transnitrosylation consensus motif
at cysteine amino acid residue 1718 [13]. However,
whether 1718 cysteine in ZO-1 is nitrosylated and the
consequent effect this nitrosylation would have on BBB
integrity are not known.
Traits of the BBB suggest that the effect of a contusion may
be disruptive, and disruption of BBB is one of the major
causes of secondary injury. After BBB compromise,
unwanted cells, debris, and water transmigrate across and
infiltrate the BBB, which finally leads to edema, a promi-
nent cause of mortality following TBI. In this study,
GSNO decreased edema, likely via BBB protection (Fig
2C). Blood leakage into the parenchyma through the
compromised BBB contributes further to inflammation,
disrupting cellular defense mechanisms. Blood is also a
rich source of iron, which catalyzes free radical (hydroxyl
radical) formation, causing instant lipid peroxidation-
mediated cell death. Lipid peroxidation, which goes
hand-in-hand with inflammation in injured brain tissue,
was decreased by the treatment of GSNO in a rat model of
experimental stroke [6].
Inflammation, an essential component of TBI, is involved
not only in BBB disruption and apoptotic cell death but
also hinders the recovery of neurobehavioral functions.
Inhibition of cytokine production by anti-inflammatory
agents, including minocycline and statins, has been
shown to reduce TBI [52,72]. Among the inflammatory
mediators, iNOS induction and the consequent product
peroxynitrite have been implicated in TBI. Peroxynitrite is
formed via a diffusion-limited reaction of superoxide and
NO, which damages biomolecules by nitrotyrosine for-
mation. As a consequence, the levels and bioavailability
of NO are decreased. Reduction of peroxynitrite via perox-
ynitrite-reducing agents, including tempol, protects
against TBI, indicating the deleterious role of peroxynitrite
[73]. Expression of iNOS has been found near necrotic
and inflammatory areas mainly in neutrophils/macro-
phages, where it plays a crucial role in secondary brain
damage subsequent to TBI in humans [74], and inhibition
of iNOS has protected against injury in TBI animal models
[73,75]. We observed that GSNO inhibited the expression
of iNOS after the injury (Fig 3), indicating that GSNO has
potential to protect the brain against iNOS-mediated neu-
rodegeneration in TBI. We have previously also docu-
mented the inhibitory effect of GSNO on iNOS induction
in the brain following IR and in rat primary astrocytes and
microglial cell lines in culture [7]. The inhibition of NF-κB
by GSNO indicates that GSNO may exert an iNOS inhib-
itory effect in an NF-κB dependent pathway [7].
Effect of GSNO on neuronal apoptotic cell death (TUNEL  assay) at 72 h after CCI Figure 5
Effect of GSNO on neuronal apoptotic cell death 
(TUNEL assay) at 72 h after CCI. Traumatic penumbral 
region in CCI+VEH brain had a significantly higher number of 
TUNEL positive cells compared to CCI+GSNO treated 
brain. Sham brain had no TUNEL positive cells (A). TUNEL 
positive cells were found to colocalize with neuronal marker 
NSE (B). Number of TUNEL positive cells (C) and number of 
stained positive cells (D) were counted in three different 
fields and averaged. Data are presented as mean ± SD 
TUNEL staining was carried out as described in Methods. 
Photomicrographs are the representative of n = 3 in each 
group. **p < 0.01 vs. Sham and CCI+GSNO.Journal of Neuroinflammation 2009, 6:32 http://www.jneuroinflammation.com/content/6/1/32
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Therefore, the major focus of TBI research should be pro-
tection of neurons from apoptotic cell death by reducing
the secondary injury of inflammation and oxidative stress.
We have previously reported in our stroke study the
potent anti-apoptotic action of GSNO, which likely occurs
through GSNO-mediated inhibition of inflammation and
caspase-3 activity [7]. GSNO has been known to inhibit
the activity of caspase-3 via its nitrosylation [76]. In this
study, GSNO also reduced neuronal apoptotic cell death
(Fig 5), indicating mechanisms in TBI similar to stroke.
Inflammation is an intrinsic modulator of events which
cause neurological deficits and cell death following TBI
[51,52]. Improvements in motor functions are the signifi-
cant indications and endpoint result to determine the effi-
cacy of a therapeutic after acute injury. Therefore, we next
examined whether our biochemical results were consist-
ent with neurobehavioral recovery. Three different tests
were performed at regular intervals (Fig 4) to assess the
functional deficit and recovery of functions of the injured
(CCI+VEH) and GSNO-treated (CCI+GSNO) rats. Motor
functions, as evaluated by rotarod task, started improving
from day 3 (Fig 4A), which correlated well with the integ-
rity of BBB (Fig 2A), edema (Fig 2C), inflammation (Fig
3), and neuronal cell death (Fig 5). A gradual but contin-
uous improvement of motor function together with the
recovery of sensorimotor functions (Fig 4C) and cogni-
tion (Fig 4B) indicate that GSNO-mediated mechanisms
promote recovery and enhance repair mechanisms. In
sum, the data from neurobehavioral evaluations accord
with the protection of BBB and down regulation of events
associated with secondary injury, and these data strongly
support the efficacy of GSNO for TBI therapy.
Conclusion
GSNO protects against TBI by reducing the exacerbations
in the neurovascular unit which are involved in induction
of BBB leakage, cell death, and neurobehavioral deficits in
rats following CCI.
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